Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $1.08 billion. The enterprise value is $763.64 million.
| Market Cap | 1.08B |
| Enterprise Value | 763.64M |
Important Dates
The last earnings date was Tuesday, May 14, 2024, after market close.
| Earnings Date | May 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 47.04 million shares outstanding. The number of shares has increased by 127.09% in one year.
| Shares Outstanding | 47.04M |
| Shares Change (YoY) | +127.09% |
| Shares Change (QoQ) | +2.08% |
| Owned by Insiders (%) | 6.78% |
| Owned by Institutions (%) | 92.74% |
| Float | 18.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.47, with zero debt.
| Current Ratio | 13.47 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.80% and return on invested capital (ROIC) is -29.30%.
| Return on Equity (ROE) | -28.80% |
| Return on Assets (ROA) | -27.00% |
| Return on Capital (ROIC) | -29.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 46 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.20% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | +15.20% |
| 50-Day Moving Average | 18.88 |
| 200-Day Moving Average | 15.36 |
| Relative Strength Index (RSI) | 58.89 |
| Average Volume (30 Days) | 307,485 |
Short Selling Information
The latest short interest is 4.73 million, so 10.06% of the outstanding shares have been sold short.
| Short Interest | 4.73M |
| Short Previous Month | 4.64M |
| Short % of Shares Out | 10.06% |
| Short % of Float | 26.11% |
| Short Ratio (days to cover) | 9.27 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -93.10M |
| Pretax Income | -79.60M |
| Net Income | -79.60M |
| EBITDA | -78.90M |
| EBIT | -79.60M |
| Earnings Per Share (EPS) | -$1.92 |
Balance Sheet
The company has $320.56 million in cash and no debt, giving a net cash position of $320.56 million or $6.82 per share.
| Cash & Cash Equivalents | 320.56M |
| Total Debt | n/a |
| Net Cash | 320.56M |
| Net Cash Per Share | $6.82 |
| Equity / Book Value | 317.71M |
| Book Value Per Share | 6.75 |
| Working Capital | 312.17M |
Cash Flow
In the last 12 months, operating cash flow was -$63.79 million and capital expenditures -$138,000, giving a free cash flow of -$63.92 million.
| Operating Cash Flow | -63.79M |
| Capital Expenditures | -138,000 |
| Free Cash Flow | -63.92M |
| FCF Per Share | -$1.52 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -127.09% |
| Shareholder Yield | -127.09% |
| Earnings Yield | -7.34% |
| FCF Yield | -5.90% |
Analyst Forecast
The average price target for ELVN is $34.00, which is 47.57% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.00 |
| Price Target Difference | 47.57% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 24, 2023. It was a reverse split with a ratio of 1:4.
| Last Split Date | Feb 24, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |